Avaxim
Description
AVAXIM® INACTIVATED HEPATITIS A VACCINE ADSORBED I.P. (80U)
Avaxim consist of inactivated Hepatitis A VIRUS ( GBM strain) adsorbed on aluminium hydroxide gel. The vaccine is indicated for prevention of the infection caused by the hepatitis A virus in children aged from 12 months to 15 years inclusive.
Immunization Guideline:
One primary dose should be followed by a booster injection 6 to 18 months later.
Site of injection is deltoid muscle. Do not inject by intravascular or intradermal route. In exceptional cases, the vaccine may be administered by the subcutaneous route in patients suffering from thrombocytopenia or in patients at risk of haemorrhage.This vaccine is not to be injected into the buttocks. This vaccine must not be mixed with other vaccines in the same syringe. Shake before injection, until a homogenous suspension is obtained.
The recommended dose is 0.5 ml for each injection.
Additional information
country-of-manufacture | France |
---|---|
contraindications | An allergy to the active substance, to one of the excipients, to neomycin, to polysorbate, or shown hypersensitivity following a previous injection of this vaccine. |
manufacturer | Sanofi Pasteur |
package-size | 1 Dose |
pharmaceutical-form | Liquid |
preservative | formaldehyde, Phenoxyethanol, |
route-of-administration | Intramuscular |
vaccine-type | Hepatitis A |